Analysis of weak points in oncogenic tyrosine kinase-dependent growth

点击翻译按钮获取中文摘要

The ectopically expressed fibroblast growth factor receptor 3 (FGFR3) and its constitutive active mutations have been detected in patients with multiple myeloma (MM). This study investigated whether the cytotoxic effects of bortezomib on malignant plasma cells are associated with FGFR3 expression andthe existence of mutations of FGFR3. Materials and Methods: Cell apoptosis assays were performed in a plasmacytoma cell line, FR4 cells and a myeloma cell line, RPMI8226 cells overexpressing wild-type FGFR3 (FGFR3WT) or two different mutants, FGFR3K650E or FGFR3Y373C, and the induction of endoplasmic reticulum (ER) stress protein was compared between each type of cells. Results: FR4 cells with FGFR3K650E showed enhanced sensitivity to bortezomib together with increased induction of ER stress proteins, compared to FR4 cells with mock, FGFR3WT or FGFR3Y373C. RPMI8226 cells with FGFR3K650E also showed enhanced bortezomib sensitivity. Conclusion: This study indicated that FGFR3K650E is associated with bortezomib sensitivity in malignant plasma cells via ER stress pathways.